[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Martini Hospital Groningen\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":134},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,46,76,108],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":4},"100627219","phase-4-smart-verapaf-self-management-and-random-therapy-with-verapamil-or-metoprolol-in-paroxysmal-atrial-fibrillation-100627219",false,"NCT07445789","SMART-VERAPAF: Self-MAnagement and Random Therapy With VERApamil or Metoprolol in Paroxysmal Atrial Fibrillation","SMART-VERAPAF","7.2 Inclusion criteria\n\nIn order to be eligible to participate in this study, a subject must meet all of the following criteria:\n\n* Age ≥ 18 years old\n* ECG documented diagnosis of paroxysmal AF\n* Presence of symptomatic paroxysmal AF, defined as recurrent self-terminating AF (≥ 2 episodes in last 4 months) documented by typical symptoms, ECG or photoplethysmo-gram\n* Able and willing to sign informed consent.\n\nFor SMART sub study only:\n\n\\- Own a smartphone\n\n7.3 Exclusion criteria\n\nA potential subject who meets any of the following criteria will be excluded from participation in this study:\n\n* A history of electrical cardioversion for persistent AF\n* History of AF episode \\> 7 days\n* Previous or current chronic amiodaron use.\n* A history of pulmonary vein ablation\n* Taking part in another randomized trial\n* Reduced life-expectancy of \\\u003C 1 year\n* Presence of contra-indication for verapamil or metoprolol\n* Pregnant or breastfeeding women. Or women who are planning to become pregnant during the study period.\n* For substudy patients: already participating in an eHealth program\n\nContraindications for verapamil or metoprolol:\n\n* Known hypersensitivity, intolerance or allergy to verapamil, metoprolol, or any excipi-ents.\n* Current use of verapamil, diltiazem, beta-blockers or digoxin, or \\\u003C 5 half-lives ago at the time of randomization.\n* Concomitant use of medications with absolute contraindications for verapamil or metoprolol (e.g., strong CYP3A4 inhibitors).\\*\n* Resting heart rate \\\u003C 50 beats per minute at baseline.\n* Symptomatic hypotension (or systolic blood pressure \\\u003C 100 mmHg).\n* Second- or third-degree atrioventricular block.\n* Sick sinus syndrome or sinus node disease.\n* Wolff-Parkinson-White syndrome.\n* Severe heart failure (NYHA class III-IV or left ventricular ejection fraction \\\u003C 45%).\n* Clinically significant constipation requiring medical intervention.\n* Severe bronchial asthma or COPD with bronchial hyperreactivity.\n* Untreated pheochromocytoma (unless patient is concomitantly treated with an α-blocker).\n* Type 1 diabetes mellitus with frequent symptomatic hypoglycaemia where β-blocker use would pose unacceptable risk due to masking of symptoms.\n* Severe symptomatic peripheral arterial disease or disabling Raynaud's phenomenon.\n* Pacemaker therapy in place. An implanted loop recorder is not a contraindication.\n* Severe hepatic impairment (Child-Pugh class C).\n* Severe renal impairment (eGFR \\\u003C 30 ml\u002Fmin\u002F1.73m²). \\*Patients using statins can be switched to an equivalent dose of rosuvastatin prior to ran-domization. Patients using oral anticoagulation need to be switched to apixaban or rivaroxa-ban.","ALL","18 Years",{"count":19,"type":20},436,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","The SMART-VERAPAF study investigates the effects of different heart rate-lowering medications in patients with paroxysmal atrial fibrillation (AF). This heart rhythm disorder is associated with a large number of emergency room visits and hospitalizations for cardioversions and ablations. In this study, patients with symptomatic paroxysmal AF are randomized to treatment with heart rate reduction using verapamil or metoprolol, both licensed for this indication. In addition, in a subset of patients, the effect of centrally guided self-care using smartwatch data will be evaluated.\n\nThe hypothesis is that both verapamil and guided self-care will lead to better heart rate control and fewer cardioversions and pulmonary vein ablations in patients with paroxysmal AF. This will also result in fewer hospital admissions, outpatient visits, and costs, as well as improved quality of life.",[26],"Atrial Fibrillation (AF)",[28,29,30,31,32,33],"atrial fibrillation","verapamil","metoprolol","rate control","rhythm control","paroxysmal","NOT_YET_RECRUITING","2026-03-23",{"date":37,"type":38},"2026-03-27","ACTUAL",{"date":40,"type":20},"2026-06",{"date":42,"type":20},"2029-06",{"name":44,"class":45},"Martini Hospital Groningen","OTHER",{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":53,"targetDuration":55,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":61,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},"100509340","spect-ct-vs-mri-for-the-diagnosis-of-osteoarthritis-in-the-foot-and-ankle-100509340","NCT05912153","SPECT-CT vs MRI for the Diagnosis of Osteoarthritis in the Foot and Ankle","SPECT-CT Versus MRI for the Diagnosis of Symptomatic Osteoarthritis in the Ankle, Hind- and Midfoot.","Inclusion Criteria:\n\n* Suspected symptomatic ankle, hind- or midfoot OA\n* Informed consent\n* Age ≥ 18 years\n* Average NRS ≥4 over the past week.\n\nExclusion Criteria:\n\n* Contraindication for surgery\n* Contraindication for SPECT-CT or MRI\n* Contraindication for intra-articular injections\n* Isolated forefoot pathology\n* Fracture, ligamentous or tendon injury of the ankle, hind- and\u002For midfoot trauma within one year before presentation\n* History of neurological disease\n* History of foot and\u002For ankle surgery (affected side)\n* Inability to read and understand the written information",{"count":54,"type":20},132,"1 Year","OBSERVATIONAL","The diagnose of symptomatic osteoarthritis in the ankle, mid- and hind foot remains challenging. There is no gold standard for the work-up and various hospitals use different protocols. Current literature shows a promising role for SPECT-CT imaging in ankle, hind- and midfoot OA. In a previous study investigating the role of SPECT-CT in a reproducible group we have observed a change in diagnosis in 53% when SPECT-CT data was added to the data of conventional workup alone. In 26% of patients addition of SPECT-CT data resulted in change of the original treatment plan. To our knowledge no prospective studies are available on this subject for both SPECT-CT and MRI. In our clinic both SPECT-CT and MRI are used in the work-up for patients with ankle, hind- and midfoot pain. Although we experience good result with SPECT-CT, MRI might be able to detect symptomatic OA as well. Moreover MRI provide more information about soft tissue and is less harmful for the patient in comparison to SPECT-CT. The aim of this study is to determine the diagnostic performance of SPECT-CT and MRI when used routinely in patients with symptomatic OA of the ankle, hind- and midfoot.",[59,60],"Osteoarthritis Ankle","Osteoarthritis",[62,63,64,65],"SPECT\u002FCT","MRI","osteoarthritis","Foot and\u002For Ankle","RECRUITING","2026-02-24",{"date":69,"type":38},"2026-02-27",{"date":71,"type":38},"2023-07-04",{"date":73,"type":20},"2027-12",{"name":44,"class":45},1,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":83,"sex":84,"minAge":85,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":89,"conditions":90,"keywords":94,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},"100564819","cycling-through-the-menstrual-cycle-100564819","NCT06634134","Cycling Through the Menstrual Cycle","Hoe Fietst de Vrouwelijke Wielrenner Door Haar Menstruatiecyclus?","Inclusion Criteria:\n\n* JOIN cycling app member\n* female cyclist\n* informed consent period tracking in JOIN\n\nExclusion Criteria:\n\n* none",true,"FEMALE","12 Years","60 Years",{"count":88,"type":20},750,"With an increase in number of female athletes in sport events, it is becoming more important to gain insight in female related sports physiology. A main difference between male anf female athletes is the menstrual cycle. During the menstrual cycle, female reproductive hormones fluctuate. These hormones are also of influence on endurance, recovery, muscle strenght and mental state. Therefore we hypothesize that training efficiancy, power and motivation to train differ during the menstrual cycle. In case there is a pattern seen during the menstrual cycle, training programs can be individualized taking the menstrual cycle into account leading to more effective training programs.",[91,92,93],"Menstrual Cycle-based Periodized Training","Female Athlete Triad","Menstrual Cycle",[93,95,96,92,97,98],"Artificial Intelligence","Cycling","Female Athletes","Menstrual Cycle-based Periodized training","2025-07-24",{"date":101,"type":38},"2025-07-28",{"date":103,"type":38},"2024-10-10",{"date":105,"type":20},"2028-01-01",{"name":44,"class":45},2,{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":16,"minAge":116,"maxAge":117,"enrollmentInfo":118,"targetDuration":4,"studyType":21,"phases":120,"briefSummary":122,"conditions":123,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":75},"100499595","clinical-versus-home-introduction-of-milk-in-children-with-non-ige-mediated-cows-milk-allergy-100499595","NCT05785299","Clinical Versus Home Introduction of Milk in Children with Non-IgE-mediated Cow's Milk Allergy","Evaluation of the Outcome of Clinical or Home Introduction of Milk in Children with Non-IgE-mediated Cow's Milk Allergy (ENIGMA Trial)","ENIGMA","Inclusion Criteria:\n\n* maximum age of eighteen months;\n* suspected to be allergic for cow's milk (based on medical history);\n\nExclusion Criteria:\n\n* children older than the age of eighteen months;\n* sensitised for cow's milk (i.e. SPT \\>3mm (in combination with positive control ≥3mm) or specific IgE \\>0.35 kU\u002FL)\n* patient suffers from acute (i.e. within one hour after cow's milk had been eaten) and moderate-severe IgE-mediated symptoms after ingestion of cow's milk\n* patient suffers from symptoms according to the FPIES criteria after ingestion of cow's milk\n* patient uses beta blockers and\u002For prednisolone;\n* patient suffers from uncontrolled respiratory symptoms or severe eczema or a chronic condition because of which the patients cannot be included as judged by the treating physician;\n* parents are unable to adequately report the occurrence of possible symptoms (e.g. insufficient language proficiency).","1 Month","18 Months",{"count":119,"type":20},120,[121],"NA","There are a lot of parents who believe that their child may not tolerate cow's milk because they develop symptoms such as redness of the skin or they may vomit. It is not always easy to find out if these infants should indeed avoid drinking cow's milk or that the symptoms are caused by something else, for instance because they have a viral illness. The goal of the investigators is to find out if cow's milk should be introduced in the hospital or if it can also be advised to perform the introduction at home to determine if an infant can drink cow's milk without developing symptoms. Half of the participants will drink cow's milk in the hospital. This test is performed on two days. On one of the days cow's milk will be offered. On the other day a look-alike substance is offered. The other half of the participants will drink cow's milk at home by starting to drink a little bit of milk and in a few steps drink a normal bottle of cow's milk. The main question is whether both tests can be used to find out if an infant can drink cow's milk without developing symptoms.",[124,125],"Cow Milk Allergy","Food Allergy","2024-11-21",{"date":128,"type":38},"2024-11-25",{"date":130,"type":38},"2023-10-09",{"date":132,"type":20},"2026-06-01",{"name":44,"class":45},""]